Division of Vectura Group PLC
Latest From SkyePharma PLC
Pacira believes new clinical trial of post-surgical pain medication will satisfy FDA concerns raised in complete response letter for its supplemental NDA.
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
Respiratory specialist Vectura has shrugged off disappointing Phase III results of Flutiform in COPD that could preclude the therapy’s use in that indication, saying that all hope is not yet lost and that the impact will be marginal in any case given Flutiform’s rising sales in treating asthma.
Skyepharma's outgoing CEO Peter Grant, has been masterminding the company's return to profitability for a decade. He looks back on how he negotiated pharma's financial waters and how that led to the company's merger with UK competitor Vectura.
- Medical Devices
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Vectura Group PLC
- Senior Management
Peter Grant, CEO
Andrew Derodra, CFO
Kirsten Kaiser, EVP, Medicinal & Regulatory
Geraldine Venthoye, EVP, Pharmaceutical Dev.
Guy Vergnault, VP, Oral Drug Delivery Solutions
Selene Daly, VP, Supply Chain
Christian Pangratz, EVP, BD and Alliances
- Contact Info
Phone: (44) 207 881 0524
46-48 Grosvenor Gardens
London, SW1W 0EB
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.